Table 1 Patient characteristics of primary AML samples for flow cytometric analysis
From: Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
All cases | Initial Dx | Relapse | |
|---|---|---|---|
Samples, n | 356 | 302 | 54 |
Age, median (range) | 63 (16–92) | 65 (16–92) | 55 (23–80) |
Gender, n (%) | |||
Male | 201 (56%) | 170 (56%) | 31 (57%) |
Female | 155 (44%) | 132 (44%) | 23 (43%) |
FAB, n (%) | |||
M0 | 18 (8%) | 12 (7%) | 6 (19%) |
M1 | 68 (32%) | 61 (34%) | 7 (23%) |
M2 | 45 (21%) | 40 (22%) | 5 (16%) |
M3 | 9 (4%) | 8 (4%) | 1 (3%) |
M4 | 41 (19%) | 35 (19%) | 6 (19%) |
M5 | 30 (14%) | 24 (13%) | 6 (19%) |
M6 | 2 (1%) | 2 (1%) | 0 (0%) |
M7 | 0 (0%) | 0 (0%) | 0 (0%) |
Unknown | 143 | 120 | 23 |
Cytogenetics, n (%) | |||
Normal karyotype | 139 (43%) | 123 (44%) | 16 (36%) |
Complex karyotype | 73 (23%) | 60 (21%) | 13 (30%) |
t(8;21) | 9 (3%) | 9 (3%) | 0 (0%) |
t(9;11)(p21-22;q23) or t(11;19)(q23;p13) | 10 (3%) | 9 (3%) | 1 (2%) |
inv(16)/t(16;16)(p13;q22) | 9 (3%) | 9 (3%) | 0 (0%) |
Other adverse risk abnormalities | 22 (7%) | 17 (6%) | 5 (11%) |
Non-classified abnormalities | 62 (19%) | 53 (19%) | 9 (20%) |
Unknown | 32 | 22 | 10 |
Mutations (normal karyotype), n (%) | |||
NPM1 mut/FLT3 wt | 38 (28%) | 37 (31%) | 1 (6%) |
NPM1 mut/FLT3-ITD | 35 (26%) | 30 (25%) | 5 (31%) |
NPM1 wt/FLT3-ITD | 14 (10%) | 14 (12%) | 0 (0%) |
NPM1 wt/FLT3 wt | 50 (36%) | 40 (33%) | 10 (63%) |
CEBPA mut | 6 (10%) | 6 (10%) | 0 (0%) |
KMT2A mut | 16 (12%) | 12 (10%) | 4 (22%) |
MRC, n (%) | |||
Favorable | 46 (14%) | 44 (16%) | 2 (4%) |
Intermediate | 178 (55%) | 154 (55%) | 24 (53%) |
Adverse | 100 (31%) | 81 (29%) | 19 (42%) |
Unknown | 32 | 23 | 9 |
ELN2010, n (%) | |||
Favorable | 64 (20%) | 62 (23%) | 2 (4%) |
Intermediate-I | 90 (28%) | 74 (27%) | 16 (36%) |
Intermediate-II | 64 (20%) | 55 (20%) | 9 (20%) |
Adverse | 100 (31%) | 82 (30%) | 18 (40%) |
Unknown | 38 | 29 | 9 |
